Abstract
The intention of this chapter is to provide an outline of the regulatory and legislative background to drug development. It is not aimed at regulatory professionals but rather at the research scientist who, while being aware that the pharmaceutical industry is probably the most regulated and restricted of all industries, knows little of the detail of what is involved — or why.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
British Medical Association (1909) Secret remedies: what they are and what they contain. British Medical Association, London
Mann RD (1984) An equiry on historical principles. MTP Press, London
Penn RG (1979) The state control of medicines: the first 3000 years. Br J Clin Pharmacol 8: 293–305
Select Committee on Patent Medicines (1914) Report of the Select Committee on Patent Medicines. HMSO, London
Snoddy CS, Michalak RA, Kaufman LS (1985) The pyramid concept. Drug Information J 19: 27 - 33
Wardell WM, Lasagna L (1975) Regulation and drug development. American Enterprise Institute, Washington
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Eardley, S.C. (1990). Regulatory Procedures. In: Ryley, J.F. (eds) Chemotherapy of Fungal Diseases. Handbook of Experimental Pharmacology, vol 96. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75458-6_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-75458-6_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-75460-9
Online ISBN: 978-3-642-75458-6
eBook Packages: Springer Book Archive